Viracta Therapeutics Announces Departure of Chief Medical Officer
May 02 2023 - 4:05PM
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology
company focused on the treatment and prevention of virus-associated
cancers that impact patients worldwide, today announced that Chief
Medical Officer, Lisa Rojkjaer, M.D., will be leaving the company
to pursue another opportunity, effective May 5, 2023. Donald
Strickland, M.D., Viracta’s Vice President, Clinical Development
and Medical Director, and Yisrael Katz, M.D., Senior Medical
Director, will continue to oversee Viracta’s pivotal NAVAL-1 trial
and solid tumor clinical program, respectively.
“Viracta has built an excellent team of talented
professionals that have achieved important milestones such as the
initiation and global expansion of Nana-val’s pivotal NAVAL-1 trial
in EBV-positive relapsed/refractory lymphoma in addition to the
advancement of our Nana-val program into EBV-positive solid
tumors,” said Mark Rothera, President and Chief Executive Officer
of Viracta. “I have the utmost confidence that this team will
continue to efficiently advance the development of Nana-val as a
potentially tumor agnostic therapy for EBV-associated cancers. I
would like to thank Lisa for her contributions to Viracta and wish
her well in her next endeavor.”
About Viracta Therapeutics,
Inc.Viracta is a precision oncology company focused on the
treatment and prevention of virus-associated cancers that impact
patients worldwide. Viracta’s lead product candidate is an all-oral
combination therapy of its proprietary investigational drug,
nanatinostat, and the antiviral agent valganciclovir (collectively
referred to as Nana-val). Nana-val is currently being evaluated in
multiple ongoing clinical trials, including a pivotal, global,
multicenter, open-label Phase 2 basket trial for the treatment of
multiple subtypes of relapsed/refractory Epstein-Barr
virus-positive (EBV+) lymphoma (NAVAL-1), as well as a
multinational, open-label Phase 1b/2 trial for the treatment of
EBV+ recurrent or metastatic nasopharyngeal carcinoma and other
EBV+ solid tumors. Viracta is also pursuing the application of its
“Kick and Kill” approach in other virus-related cancers.
For additional information please visit
www.viracta.com.
Forward Looking StatementsThis communication
contains "forward-looking" statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including,
without limitation, statements regarding: the details, timeline and
expected progress for Viracta's ongoing and anticipated trials and
updates regarding the same, including NAVAL-1 and the Phase 1b/2
trial of Nana-val in EBV+ solid tumors, the announced changes to
management, statements concerning or implying Viracta’s future
performance, goals and potential, and the ability of management
personnel to contribute to the execution of Viracta’s vision,
performance, goals and potential. Risks and uncertainties related
to Viracta that may cause actual results to differ materially from
those expressed or implied in any forward-looking statement
include, but are not limited to: Viracta's ability to successfully
enroll patients in and complete its ongoing and planned clinical
trials; Viracta's plans to develop and commercialize its product
candidates, including all oral combinations of nanatinostat and
valganciclovir; the timing of initiation of Viracta's planned
clinical trials; the timing of the availability of data from
Viracta's clinical trials; previous preclinical and clinical
results may not be predictive of future clinical results; the
timing of any planned investigational new drug application or new
drug application; Viracta's plans to research, develop and
commercialize its current and future product candidates; the
clinical utility, potential benefits and market acceptance of
Viracta's product candidates; Viracta's ability to manufacture or
supplying nanatinostat, valganciclovir and pembrolizumab for
clinical testing; Viracta's ability to identify additional products
or product candidates with significant commercial potential;
developments and projections relating to Viracta's competitors and
its industry; the impact of government laws and regulations;
Viracta's ability to protect its intellectual property position;
and Viracta's estimates regarding future expenses, capital
requirements and need for additional financing in the future.
These risks and uncertainties may be amplified
by the COVID-19 pandemic, which has caused significant economic
uncertainty. If any of these risks materialize or underlying
assumptions prove incorrect, actual results could differ materially
from the results implied by these forward-looking statements.
Additional risks and uncertainties that could cause actual outcomes
and results to differ materially from those contemplated by the
forward-looking statements are included under the caption "Risk
Factors" and elsewhere in Viracta's reports and other documents
that Viracta has filed, or will file, with the SEC from time to
time and available at www.sec.gov.
The forward-looking statements included in this
communication are made only as of the date hereof. Viracta assumes
no obligation and does not intend to update these forward-looking
statements, except as required by law or applicable regulation.
Investor Relations Contact:Ashleigh BarretoHead
of Investor Relations & Corporate CommunicationsViracta
Therapeutics, Inc.abarreto@viracta.com
SOURCE Viracta Therapeutics, Inc.
Viracta Therapeutics (NASDAQ:VIRX)
Historical Stock Chart
From Apr 2024 to May 2024
Viracta Therapeutics (NASDAQ:VIRX)
Historical Stock Chart
From May 2023 to May 2024